Registry for patients with myeloproliferative neoplasms
Clinical and Molecular Epidemiology of Myeloproliferative Neoplasms (MPNs)
This study is creating a database to gather information from people with myeloproliferative neoplasms to help improve treatments and outcomes for these rare blood cancers.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 5000 (estimated) |
| Sex | All |
| Sponsor | University Health Network, Toronto Academic / other |
| Locations | 1 site (Toronto, Ontario) |
| Trial ID | NCT02760238 on ClinicalTrials.gov |
What this trial studies
This registry collects clinical information and molecular results from patients diagnosed with various myeloproliferative neoplasms (MPNs) over time. It aims to establish a comprehensive database that enhances understanding of these rare hematological malignancies and improves patient outcomes by optimizing therapy assignments. Data will be gathered both prospectively and retrospectively, including clinical measures, treatment details, complications, and survival outcomes. The registry will serve as a valuable resource for future observational studies related to MPNs.
Who should consider this trial
Good fit: Ideal candidates for this registry are patients diagnosed with any type of myeloproliferative neoplasm.
Not a fit: Patients without a diagnosis of myeloproliferative neoplasms will not benefit from this registry.
Why it matters
Potential benefit: If successful, this registry could lead to improved treatment strategies and outcomes for patients with myeloproliferative neoplasms.
How similar studies have performed: Other studies have shown success with similar observational approaches in understanding hematological malignancies, making this registry a valuable addition to existing research.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: Diagnosis of one of the following myeloproliferative neoplasms (MPNs): * Atypical CML (aCML) * Chronic eosinophilic leukemia-not otherwise specified (CEL, NOS), * Chronic myelomonocytic leukemia (CMML) * Chronic neutrophilic leukemia (CNL), * Essential thrombocythemia (ET), * Juvenile myelomonocytic leukemia (JMML), * Mastocytosis, MPN unclassifiable * MPN/MDS unclassifiable, * Primary myelofibrosis (PMF), * Post-essential thrombocythemia myelofibrosis (post-ET MF), * Post-polycythemia vera MF (post-PV MF) * Refractory anemia with ringed sideroblasts associated with marked thrombocytosis (RARS-T) Exclusion Criteria: * None
Where this trial is running
Toronto, Ontario
- Princess Margaret Cancer Centre — Toronto, Ontario, Canada (Recruiting)
Study contacts
- Principal investigator: Vikas Gupta, MD — University Health Network, Toronto
- Study coordinator: Vikas Gupta, MD
- Email: vikas.gupta@uhn.ca
- Phone: 416-946-4521
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.